Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
  1. All Episodes
  2. Partners in the Continuum of Drug Development with Gabriele Brambilla AliraHealth

Partners in the Continuum of Drug Development with Gabriele Brambilla AliraHealth

Jul 27, 2022

Gabriele Brambilla is the CEO and Executive VP of AliraHealth and is looking for ways to humanize healthcare and involve patients in the entire drug development continuum. They deliver services to drug developers, medical device developers, and digital health solution providers.

Gabriele explains, "We call it democratization of life sciences research, the ability to use our technology to directly involve patients, in different phases of development of a drug or a device, in a very active partnership, not just a passive collection of data."

"So AliraHealth provides a continuum of services that starts from the very early phases of development of a drug or a device. And a drug would be for us the CMC, which is chemistry manufacturing control. It would go then to regulatory, so we help our clients to interact with the FDA, or EMA for Europe, and then register the drugs. And we run clinical trials for our clients and market access. Also the ability to deliver value and effectiveness in front of payers so that they can actually reimburse for the drug and give access to patients to the drug."

@AliraHealth #PatientCentric #DigitalHealth #DecentralizedClinicalTrials #Digitaltx #DrugDevelopment

AliraHealth.com

Download the transcript here

AliraHealth